SCHEMBL4888995

SCHEMBL4888995

S=C1NC(c2ccoc2)(c2cccc(Br)c2)C2=NCCCN12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 11/20 0.41
CTSD P07339 5/20 0.41
BACE2 Q9Y5Z0 7/20 0.35
APP P05067 1/20 0.35
HDAC8 Q9BY41 3/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
CHRNA1 P02708 1/20 0.31
CHRNG P07510 1/20 0.31
CHRNB1 P11230 1/20 0.31
CHRNB2 P17787 1/20 0.31
SLC6A2 P23975 1/20 0.31
CHRNB4 P30926 1/20 0.31
SLC6A4 P31645 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
SLC6A3 Q01959 1/20 0.31
CHRND Q07001 1/20 0.31
POLB P06746 2/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883509 0.87 BACE1 (0.45) BACE1CTSDBACE2APPHDAC8
SCHEMBL4882001 0.84 BACE1 (0.43) BACE1CTSDBACE2APPHDAC8
SCHEMBL4889010 0.84 BACE1 (0.45) BACE1CTSDBACE2APPHDAC8
SCHEMBL4892270 0.84 BACE1 (0.41) BACE1CTSDBACE2APPHDAC8
SCHEMBL8224090 0.83 BACE1 (0.44) BACE1CTSDBACE2APPHDAC8
SCHEMBL4887798 0.83 BACE1 (0.44) BACE1CTSDBACE2APPHDAC8
SCHEMBL8277624 0.83 BACE1 (0.46) BACE1CTSDBACE2APPSLC6A2
SCHEMBL8275986 0.82 BACE1 (0.45) BACE1CTSDBACE2APPSLC6A2
SCHEMBL4884542 0.82 BACE1 (0.43) BACE1CTSDBACE2APPHDAC8
SCHEMBL4883739 0.82 BACE1 (0.53) BACE1CTSDBACE2APPCHRNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007145569-A9 AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA ASTRAZENECA AB (SE) 2008-12-11 WO disclosed
US-20080058349-A1 New Compounds 318 ASTRAZENECA AB (SE) 2008-03-06 US disclosed
US-20080058349-A1 New Compounds 318 ASTRAZENECA AB (SE) 2008-03-06 US disclosed
US-20080058349-A1 New Compounds 318 ASTRAZENECA AB (SE) 2008-03-06 US disclosed
US-20070299087-A1 New Compounds 319 ASTRAZENECA AB (SE) 2007-12-27 US disclosed
US-20070299087-A1 New Compounds 319 ASTRAZENECA AB (SE) 2007-12-27 US disclosed
US-20070299087-A1 New Compounds 319 ASTRAZENECA AB (SE) 2007-12-27 US disclosed
WO-2007145570-A1 AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA ASTRAZENECA AB (SE) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299087-A1 New Compounds 319 PSEN2, PSEN1, MAPT BACE1 4/4885CTSD 2006/4885BACE2 16/4885
US-20080058349-A1 New Compounds 318 PSEN2, PSEN1, MAPT BACE1 5/4885CTSD 1887/4885BACE2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.